OXiGENE Announces Data Presentation At 2009 AACR-EORTC-NCI Conference

WALTHAM, Mass., Oct. 12, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)
(XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases, announced today that interim
data from its randomized, controlled, Phase 2 study of ZYBRESTAT(TM) in
combination with Avastin(R) and chemotherapy in patients with advanced
non-small cell lung cancer will be presented in a poster session at the
upcoming AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference in
Boston, MA, November 15-18, 2009. 


 Abstract #B19
 Poster Title:  Interim Safety Results of a Randomized Phase 2
                Trial of a Tumor Vascular Disrupting Agent
                Fosbretabulin Tromethamine (CA4P) with Carboplatin,
                Paclitaxel and Bevacizumab in Stage IIIB/IV Non-
                Squamous Non Small Cell Lung cancer (NSCLC)
 Presenter:     Edward Garon, MD, Assistant Professor, Medicine,
                David Geffen School of Medicine at UCLA
 Session ID:   Poster Session B
 Session Title:    Angiogenesis and Antiangiogenesis Agents 2
 Session Date and Time:     Tuesday Nov 17, 2009 12:30 PM - 2:30 PM
 Location:    Halls C-D, 2nd Floor, Hynes Convention Center


About ZYBRESTAT

ZYBRESTAT (fosbretabulin) is currently being evaluated in a pivotal
registration study as a potential treatment for anaplastic thyroid cancer (ATC)
under a Special Protocol Assessment agreement with the U.S. Food and Drug
Administration (FDA). Phase II studies in platinum-resistant ovarian cancer and
non-small cell lung cancer are also ongoing. OXiGENE believes that ZYBRESTAT is
poised to become the first therapeutic product in a novel class of
small-molecule drug candidates called vascular disrupting agents (VDAs).
Through interaction with vascular endothelial cell cytoskeletal proteins,
ZYBRESTAT selectively targets and collapses tumor vasculature, thereby
depriving the tumor of oxygen and causing death of tumor cells. In clinical
studies in solid tumors, ZYBRESTAT has demonstrated potent and selective
activity against tumor vasculature, as well as clinical activity against ATC,
ovarian cancer, and various other solid tumors. In clinical studies in patients
with forms of macular degeneration, intravenously-administered ZYBRESTAT has
demonstrated clinical activity, and the Company is working to develop a
convenient and patient-friendly topical formulation of ZYBRESTAT for
ophthalmological indications. 

About OXiGENE

OXiGENE is a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases. The company's major focus is
developing VDAs that selectively disrupt abnormal blood vessels associated with
solid tumor progression and visual impairment. OXiGENE is dedicated to
leveraging its intellectual property and therapeutic development expertise to
bring life-extending and -enhancing medicines to patients. 

The OXiGENE, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=4969 

CONTACT:  OXiGENE, Inc.
          Investor and Media Contact:
          Investor Relations
          Michelle Edwards
          415-315-9413
          medwards@oxigene.com